Market Place
Sourcing Support
Dyadic Unveils 2025 Financials, Showcases Company Advancements
25 Mar 2026 //
GLOBENEWSWIRE
Dyadic`s Q2 2025 Financial Results and Recent Progress Highlights
13 Aug 2025 //
GLOBENEWSWIRE
Dyadic Reshapes Leadership To Focus On Ancillary Proteins
02 Jun 2025 //
GLOBENEWSWIRE
Dyadic Reports Q1 2025 Financial Results and Recent Progress
14 May 2025 //
GLOBENEWSWIRE
Dyadic Reports 2024 Financial Results and Updates
26 Mar 2025 //
GLOBENEWSWIRE
Dyadic to Report 2024 Financial Results, Host Call on March 26
12 Mar 2025 //
GLOBENEWSWIRE
Dyadic And Proliant Announce Recombinant Albumin Development Partnership
28 Jun 2024 //
GLOBENEWSWIRE
Dyadic to Attend Industry Events in June
30 May 2024 //
GLOBENEWSWIRE
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes
11 Mar 2024 //
GLOBENEWSWIRE
Dyadic to Attend Industry Events in March
01 Mar 2024 //
GLOBENEWSWIRE
Dyadic Advances Collaboration with IIBR Targeting Bio-Threats
23 Feb 2024 //
GLOBENEWSWIRE
Dyadic Advances Collaboration with IIBR Targeting Bio-Threats
21 Feb 2024 //
GLOBENEWSWIRE
Dyadic Announces R&D Agreement with Global Biopharmaceutical Company
06 Feb 2024 //
GLOBENEWSWIRE
Dyadic to Present at Industry Events in November
30 Oct 2023 //
GLOBENEWSWIRE
Dyadic Appoints Doug Pace to Its Executive Leadership Team
09 Oct 2023 //
GLOBENEWSWIRE
Dyadic to Present at Industry and Investor Events in October
29 Sep 2023 //
GLOBENEWSWIRE
Dyadic to Present at BioProcess International
12 Sep 2023 //
GLOBENEWSWIRE
Dyadic to Report Q2 2023 Financial Results on Wednesday, August 9, 2023
26 Jul 2023 //
GLOBENEWSWIRE
Dyadic to Participate at Upcoming Events in June
01 Jun 2023 //
GLOBENEWSWIRE
Dyadic Reports 2022 Year End Results and Recent Company Progress
29 Mar 2023 //
GLOBENEWSWIRE
Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023
15 Mar 2023 //
GLOBENEWSWIRE
Dyadic to Participate in Two Upcoming Investor Conferences
02 Feb 2023 //
GLOBENEWSWIRE
Dyadic Announces Sale of Equity Interest in Alphazyme
19 Jan 2023 //
GLOBENEWSWIRE
Dyadic`s DYAI-100 COVID-19 Vaccine Study Published in Peer-Reviewed Journal
14 Dec 2022 //
GLOBENEWSWIRE
Dyadic Reports 3Q 2022 Financial Results and Highlights Recent Developments
10 Nov 2022 //
GLOBENEWSWIRE
Dyadic Receives Regulatory Approval to Initiate PI Trial for DYAI-100
27 Oct 2022 //
GLOBENEWSWIRE
Dyadic to Report Q3 2022 Financial Results on Thursday, November 10, 2022
27 Oct 2022 //
GLOBENEWSWIRE
Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe
04 Oct 2022 //
GLOBENEWSWIRE
Dyadic Updates Market on Recent Scientific Achievements
13 Sep 2022 //
GLOBENEWSWIRE
Dyadic Reports Q2 Financial Results and Highlights Recent Company Developments
10 Aug 2022 //
GLOBENEWSWIRE
Dyadic to Report Second Quarter 2022 Financial Results
27 Jul 2022 //
GLOBENEWSWIRE
Dyadic to Participate in Bio-Manufacturing Innovation Summit and NIIMBL
05 Jul 2022 //
GLOBENEWSWIRE
Dyadic to Participate in Three Upcoming Industry Events
09 Jun 2022 //
GLOBENEWSWIRE
Dyadic to Present at 2022 Jefferies Healthcare Conference
02 Jun 2022 //
GLOBENEWSWIRE
Dyadic to Present at H.C. Wainwright Global Investment Conference
20 May 2022 //
GLOBENEWSWIRE
Dyadic Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Dyadic Announces Research, License and Collaboration for Animal Free Ingredients
11 May 2022 //
GLOBENEWSWIRE
Dyadic Announces Successful Toxicology Data Published in Toxicologic Pathology
09 May 2022 //
GLOBENEWSWIRE
Dyadic to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
28 Apr 2022 //
GLOBENEWSWIRE
Dyadic International to Present at Upcoming Scientific Medical Meetings
04 Apr 2022 //
GLOBENEWSWIRE
Dyadic Reports 2021 Year End Results and Recent Company Progress
29 Mar 2022 //
GLOBENEWSWIRE
Freeline Closes $26.1 M Registered Direct Offering of American Depositary Shares
15 Mar 2022 //
GLOBENEWSWIRE
Dyadic and Phibro Animal Health Announce Exclusive License Agreement
10 Feb 2022 //
GLOBENEWSWIRE
Dyadic’s CEO Mark Emalfarb to Present at BIO CEO & Investor Conference
07 Feb 2022 //
GLOBENEWSWIRE
Dyadic Reports Second Quarter 2021 Financial Results
12 Aug 2021 //
ACCESSWIRE
Dyadic’s C1 Production Platform Utilized in ZAPI Study Published in “VACCINES”
28 Jun 2021 //
GLOBENEWSWIRE
Dyadic`s DYAI-100 Advancing Towards Human Clinical Trial
18 Mar 2021 //
GLOBENEWSWIRE
